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THE IMMUNE GENETIC PROPERTIES OF THE HEALTHY ELDERLY: 
ANALYSIS ON COMMON MEFV MUTATIONS AND GENE EXPRESSION 
 
SUMMARY 
Familial Mediterranean Fever (FMF) is an autosomal recessive disease that 
commonly affects people of Mediterranean heritage. It is typically characterized by 
attacks of serositis observed in the abdomen and accompanied by fever and elevated 
acute-phase molecules. Five mutations in MEFV (the gene for FMF) namely, 
E148Q, M680I, M694V, M694I, and V726A, make up for approximately 70% of the 
disease associated alleles. However, two main observations suggest that MEFV gene 
is involved in inflammatory pathway in general and is not only specific to FMF; 1) 
increased MEFV mutation frequencies in Behçet’s disease (BD), ulcerative colitis 
(UC), rheumatoid arthritis (RA), and polyarteritis nodosa (PAN) which are chronic 
inflammatory diseases, 2) FMF protein product pyrin is involved in the anti-
inflammatory regulation pathway.  
In recent studies, relationships between MEFV mutations and MEFV expression 
levels are frequently investigated. In one of these studies, M694V mutation carriers 
were shown to have lower MEFV expression (in both healthy but carrier controls and 
FMF patients), and the expression level drops even further when two mutant alleles 
of M694V are present. In another study, it is shown that the mRNA levels of MEFV 
drop dramatically when the patients have FMF attacks. The researchers concluded 
that the decreased MEFV mRNA level is related with acute inflammation, and one 
might indicate that the lowered expression of MEFV may be responsible for the 
attacks.  
A method in studying the association between those genes, which play a role in 
inflammatory response such as MEFV and inflammation, can be the study of the 
frequency of such genes in the elderly population who have not experienced diseases 
related to FMF or rheumatoid arthritis with chronic inflammation. Here, the 
hypothesis tested is the less frequent occurrence of inflammatory gene mutations in 
the elderly population who have lived a healthy life without inflammatory disease  as 
compared to general population. So the aim of this study was to reveal any statistical 
difference in the frequencies of five most common mutations reported in MEFV 
gene, between a population of healthy elderly and historical controls representing the 
normal population. For this purpose, genotyping was done for five mutations, and the 
results were first compared with historical controls and then subgroup analyses for 
inflammation markers such as; RF (Rheumatoid Factor) and hsCRP (high sensitive 
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C-Reactive Protein) positivity versus mutation distribution were done. Furthermore, 
a gene expression analysis was done with real-time PCR, in order to reveal any 
association between mutations and expression level of MEFV. Comparison between 
the mRNA levels of MEFV was done between mutation carriers, wild type allele 
carriers and FMF patients with known MEFV mutations. 
 
 
x 
 
SAĞLIKLI YAŞLILARIN İMMÜN-GENETİK ÖZELLİKLERİ: YAYGIN 
MEFV MUTASYONLARININ VE GEN İFADESİNİN ANALİZİ 
 
 
ÖZET 
Ailesel Akdeniz ateşi (AAA), yaygın olarak Akdeniz toplumlarını etkileyen 
otozomal çekinik bir hastalıktır. Genelde karında görülen serozit atakları ve buna 
eşlik eden ateş ve yükselmiş akut-evre molekülleriyle karakterizedir. MEFV (ailesel 
akdeniz ateşi geni) geninde bulunan beş mutasyon, yani E148Q, M680I, M694V, 
M694I, ve V726A, hastalıkla alakalı alellerin yaklaşık %70’ini oluşturur. Ancak, iki  
gözlem MEFV geninin enflamatuar yolizinde bulunduğunu ve AAA’ya has 
olmadığını gösterebilir 1) Kronik iltihaplı hastalıklardan, Behçet Hastalığı (BH), 
ülseratif kolit (CH), romatoid artrit (RA) ve poliarterit nodoz (PAN) da MEFV 
mutasyon sıklığının artmış olması, 2) MEFV geninin ürünü pirin proteinin anti-
enflamatuar regülasyon yolizinde rol alması. 
Son zamanlarda yapılan çalışmalarda MEFV’deki mutasyonlarla MEFV’nin gen 
ifadesi seviyesi arasındaki ilişkiler sıkça incelenmeye başlanmıştır. Bu çalışmalardan 
birinde M694V mutasyonunu taşıyan kişilerde (hem sağlıklı taşıyıcılarda, hem de 
FMF hastası taşıyıcılarda) MEFV gen ifadesinin daha düşük olduğu bulunmuştur, 
ayrıca iki M694V mutasyonunu taşıyan kişilerde gen ifade seviyesinin çok daha fazla 
düştüğü gözlenmiştir. Başka bir çalışmada ise FMF hastalarının MEFV mRNA 
seviyelerinin ataklar esnasında, ataksız geçen döneme kıyasla çok daha düşük olduğu 
bulunmuştur. Araştırmacılar, MEFV’nin mRNA seviyesinin akut iltihapla bağlantılı 
olduğu sonucuna varmışlardır. Buradan düşük MEFV mRNA üretiminin atakların 
sorumlusu olabileceği ileri sürülebilinir.  
MEFV’nin iltihapla alakası gibi, iltihap yanıtında rol alan genlerin arasındaki 
ilişkinin analizinde kullanılabilecek metodlardan biri, daha once AAA veya 
Romatoid Artrit gibi kronik iltihaplı hastalık yaşamamış sağlıklı yaşlılarda bu 
genlerin sıklığının araştırılması olabilir. Burada sınanan varsayım iltihaplı hastalığa 
yakalanmayanlarda iltihapla ilgili genlerin serbest toplumda beklenen sıklıktan daha 
az sıklıkta olmasıdır. Dolayısıyla bu çalışmanın amacı, bir sağlıklı yaşlı grubu ile 
normal popülasyonu temsil eden tarihsel kontroller arasında, MEFV’nin en yaygın 
beş mutasyonunun sıklıkları arasında istatistiksel olarak bir farklılığın varolup 
varolmadığının ortaya çıkartılmasıdır. Bu amaçla, bu beş mutasyon genotiplendi ve 
sonuçlar önce tarihsel kontrollerle kıyaslandı, daha sonra da iltihabı işaret eden 
faktörlerden Romatoid Faktör ve C-Reaktif Protein seviyelerinin pozitivitesine 
karşılık mutasyon dağılımlarının altgrup analizleri yapıldı. Ayrıca, Gerçek-Zamanlı 
Polimeraz Zincir Reaksyonu ile mutasyonlar ve gen ifadesi seviyesi arasındaki olası 
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ilişkiler analiz edildi. MEFV mRNA seviyeleri mutasyon taşıyıcıları, mutasyonsuz 
alel taşıyıcıları ve bilinen mutasyonları taşıyan AAA hastaları arasında yapıldı.  
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1. INTRODUCTION 
1.1 Familial Mediterranean fever, MEFV gene and its product 
PYRIN/Marenostrin 
Familial Mediterranean Fever (FMF) is an autosomal recessive disease that mainly 
affects people of Mediterranean ancestry. It is one of the most common periodic 
fever syndromes. FMF is typically characterized by attacks of serositis usually in the 
abdomen; chest and joints accompanied by fever and elevated acute-phase molecules 
[1-3]. The frequency of FMF in Turkish population is determined as 1 in 1073; 
however, this value increases to 1 in 395 in the interior regions of Turkey [4].  
In 1997, the International FMF Consortium found a region of 115-kb on 
chromosome 16 via positional cloning, and declared it as the candidate region for 
FMF. MEFV (Mediterranean Fever) gene was identified within this region as the 
gene for FMF [5]. In the same year, but as a part of a separate study, French FMF 
Consortium deduced the region to 60 kb and identified four genes including MEFV 
within this region [6]. MEFV gene is found on 16p13.3, between D16S80 and 
D16S283, it is made up of 10 exons and it encodes an RNA product of 3.7-kb. The 
MEFV protein is called pyrin or marenostrin, and unspliced form of pyrin consists of 
781 amino acid residues [5,6]. Pyrin is expressed predominantly in neutrophils, 
eosinophils and cytokine-activated monocytes. There is an alternative spliced form of 
pyrin which has its 2nd exon spliced, and is 570 amino acids long [7]. Full-length 
pyrin is mainly found in the cytoplasm, while the spliced form is found in the 
nucleus. Papin suggest that pyrin is a nuclear protein and the alternative splicing of 
this protein regulate the action of mutant and wild type pyrins via altering their 
localization [7]. Mansfield reported the co-localization of full-length pyrin with the 
cytoskeletal proteins, namely microtubules and the actin cytoskeleton [8]. Pyrin 
includes four defined domains from N terminus to C terminus; (1) the PYD domain, 
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(2) the B-Box, (3) coiled-coil (CC) segments, and (4) the 160 − 170 amino acid 
B30.2 domain. The B30.2 domain overlaps with the 10th exon of MEFV gene and 
majority of the mutations observed in FMF patients lie within this region [9]. 
Recently, the B30.2 domain of pyrin is suggested to interact directly with Caspase-1, 
(Figure 1.1) and a decrease in interaction is shown related with the 10th exon 
mutations (M680I, M694V, or V726A) [10] 
 
Figure 1.1 Pyrin B30.2 domain and suggested interaction with Caspase-1 [10] 
Pyrin involves in innate immune response. It is upregulated by anti-inflammatory 
signals such as IL-10 (Interleukin 10), IL-4, (Interleukin 4) as well as 
proinflammatory signals such as Lipopolysaccharides (LPS). Pyrin is thought to be a 
suppressor of inflammation [5,6] because it uses its PYD domain to interact with 
ASC adapter protein to suppress IL-1β (Interleukin 1β) processing via interfering 
with caspase-1 activation [9]. When functional pyrin is expressed, it binds to ASC 
protein and inhibits the binding and activation of caspase-1. (Figure 1.2) But if pyrin 
is expressed in low levels or is non-functional, the caspase-1 is activated and the 
pathway leads to IL-1β processing and formation of active IL-1β, which causes the 
inflammation and the fever by stimulating the thermoregulatory center in the central 
nervous system [9,11]. 
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Figure 1.2 Domains of pyrin & Pyrin- PYD domain and interaction with ASC [9] 
1.2 MEFV mutations  
Since the cloning of the MEFV gene in 1997 [5,6], about 40 disease-associated 
mutations have been identified [12]. Five mutations in MEFV gene, E148Q, M680I, 
M694V, M694I, and V726A, make up for at least 70% of the disease associated 
alleles [13]. Some of these mutations and their localization within the MEFV gene is 
shown in Figure 1.3 below. The causes and resulting changes (if any) of five most 
common mutations are as follows: a codon change of GAG to CAG at position 148 
creates the E148Q mutation in exon 2 and causes the loss of an AvaI restriction site. 
Another codon change of ATG to ATC at position 680 creates the M680I mutation in 
10th exon, and causes HinfI restriction site loss. The codon change of GTT to GCT at 
position 726 creates the V726A mutation in 10th exon, and causes AluI restriction 
site creation. The codon change of ATG to GTG at position 694 creates the M694V 
mutation in 10th exon, whereas the change in the same codon is from ATG to ATA, it 
creates the M694I mutation [14]. 
FMF is especially predominant in Turkish, Non-Ashkenazi Jew and Armenian 
populations, which are of the Mediterranean ancestry. The approximated carrier 
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frequencies are relatively higher in these populations (1/6 in Turkish and Armenian, 
1/7 in Non-Ashkenazi Jew population) [15]. According to Yılmaz et al. the carrier 
frequency of normal Turkish population is 20% (1/5), and the frequencies of 
mutations in this normal control group are; M694V = 1.5%, M680I = 2.5%, V726A 
= 1%, M694I = 0% and E148Q = 6%, N=100, 200 chromosomes. [16] Another study 
of analyzing the mutation frequency of healthy Turkish population revealed the 
mutation frequencies as; M694V = 3.06%, M680I = 0%, V726A = 2.04%, M694I = 
0% and E148Q = 2.04%, N=49, 98 chromosomes [17]. 
 
Figure 1.3. Schematic representation of MEFV gene, exons and loci of important 
mutations [14] 
1.3 Chronic Inflammatory Diseases and MEFV Mutations 
Pyrin is thought to be an anti-inflammatory regulator found in many granulocytes. 
Mutated forms of pyrin, which cannot function properly, are frequently found in 
Familial Mediterranean fever patients, (74% of FMF chromosomes in usual cases 
consist of five most common mutations in MEFV) [13] and since pyrin is in an 
inflammatory regulation pathway the MEFV mutations can contribute to the 
occurrence of other chronic or periodic inflammatory diseases. Increased MEFV 
mutation frequencies are shown in Behçet’s disease [18,19], ulcerative colitis (UC) 
[20], rheumatoid arthritis (RA) [21], polyarteritis nodosa (PAN) [22] which are 
known chronic and periodic inflammatory diseases. MEFV mutations are found more 
frequently in BD patients (26% carried one mutant allele of either M694V, M680I or 
V726A in the study of Atagunduz et al.; M694V = 2.6%, V726A = 2.6%, E148Q = 
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5.2% in the study of Touitou et al.) than the control groups (9.1% carried one mutant 
allele of either M694V, M680I or V726A in the study of Atagunduz et al.; M694V = 
0%, V726A = 0%, E148Q = 2.2% in the study of Touitou et al) and these mutations 
are reported to be a susceptibility factor for Behçet’s disease. In Giaglis et al.’s 
study, a group of 25 untreated UC patients - as subjects, and two control groups; 28 
RA patients and 65 normal individuals, were investigated for MEFV mutations in 
exons 2 and 10. The RA control group was used as an internal control group, as it 
represents a disease that has an unaltered level of inflammation unlike the periodic 
inflammation states observed in UC. It is shown that 28% of UC patients carry at 
least one MEFV mutation; whereas, only 3.5% of RA control group and 1.5% of 
normal control group carry MEFV mutations in exon 2 and 10. Moreover, 57% of 
mutation carrier UC subjects had inflammatory arthritis, in contrast with the 
mutation free UC patients, none of whom had inflammatory arthritis. The group 
concluded that MEFV mutations may have a role in the alteration of inflammatory 
response [20]. Furthermore, Rabinovich et al. reported that the median severity score 
of RA was significantly higher in the mutation carrier group than the non-carrier 
group (p = 0.0005). It is also stated in the same study that the E148Q mutation in 
MEFV gene is an independent modifier of RA symptoms [21]. Another study that 
supports the correlation between the prevalence of MEFV mutations and 
inflammatory diseases was published by Yalcinkaya et al. in 2007. This study 
scrutinized the MEFV mutation frequencies in childhood polyarteritis nodosa 
patients. 6 common mutations of MEFV (M694V, M680I, V726A, E148Q, M694I 
and K695R) were investigated in 29 PAN patients. 38% of these 29 PAN patients 
(n=11) were shown to carry at least one MEFV mutation, and three of these were 
M694V homozygous mutants. The researchers implied that the MEFV mutations 
might become a susceptibility factor via inducing a proinflammatory state and 
increasing the immune response to streptococcal infections. 
1.4 MEFV Gene Expression Levels 
Recent studies on revealing the effects of MEFV mutations on the MEFV mRNA 
levels have given important results. Notarnicola et al. studied the effects of different 
mutations on MEFV gene expression, and found relations between the type of the 
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mutation and difference in expression level. More specifically, the healthy control 
group without the mutation had the highest MEFV expression, healthy but carrier 
group had intermediate expression; but FMF patients with mutations had 
dramatically dropped expression levels of MEFV transcript (P = 0.00001). These 
findings proposed that there is a direct relationship between the number of mutations 
in MEFV and decrease in mRNA amount. Furthermore, the studies showed that there 
is also significant difference between non-patient carriers and mutation free-controls 
(P = 0.008). The M694V mutation was revealed to be the most effective mutation in 
decreasing the expression level of MEFV mRNA. This data was both confirmed for 
FMF patients with M694V, and for healthy carriers. The study implies that the 
pathology in FMF might be caused by the aberrant MEFV expression [23]. 
Another study on MEFV expression levels was conducted by Ustek et al., which 
ascertained the changes in the expression of MEFV in normal and acute 
inflammation/FMF-attack phases. They also had a control group of 17 normally 
healthy individuals who just were having operation because of acute appendicitis. 
The results confirmed the findings of Notarnicola et. al. But additionally, this study 
showed even more decreased MEFV mRNA levels in the blood samples collected 
during the FMF attacks compared to the asymptomatic phases of the patients, which 
may indicate that the cause of the attacks being lowered expression of MEFV in the 
first place. The researchers concluded that the decreased MEFV mRNA level is 
connected with acute inflammation [24]. 
1.5 Inflammation Markers 
1.5.1 Rheumatoid Factor 
Rheumatoid Factors (RF) are autoantibodies that are usually produced in particular 
inflammatory diseases, mainly in Rheumatoid Arthritis (RA). On the other hand, RF 
production in the normal elderly people, in immunized normal people and in 
individuals with chronic inflammation or autoimmune conditions is also reported 
[25,26]. The production of RFs are accompanied by destructive joint inflammation in 
RA disease. RFs are produced in two forms: IgM (Immunoglobulin M) and IgG 
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(Immunoglobulin G) and bind to the relevant epitopes in the Fc site of 
Immunoglobulin G’s (IgGs). These RFs are found in the bound form with autologous 
IgG in the synovia of RA patients. Moreover, higher RF values have shown a 
positive relationship with the arthritis severity and progressive joint disintegration 
[25]. 
1.5.2 C-Reactive Protein 
C-reactive protein (CRP) is an acute-phase pentamer protein that is composed of five 
identical protomers, synthesized by the liver. It was first recognized by William S. 
Tillet and Thomas Francis in 1930s while observing the immune response of 
pneumococcal pneumonia patients. Normal concentration in blood serum is 0.8 
mg/L. CRP level is majorly controlled via transcriptional regulation and its 
expression is upregulated with IL-6, both reported from in vivo and in vitro studies. 
The contribution of IL-1β to upregulation of CRP expression is immense when it is 
combined with IL-6, because IL-1β enhances the translational level of regulation 
unlike IL-6. Thus, the level of CRP dramatically increases with inflammation since 
its expression depends on proinflammatory signals. As a result, CRP levels show the 
burden of inflammation [27]. In clinical investigation the CRP levels are measured 
with hsCRP (high sensitivity-C reactive Protein) test [27,28]. 
1.6 Real Time PCR 
Real Time PCR (Polymerase Chain Reaction) is a powerful tool both to observe the 
behavior of the ongoing PCR reaction and make absolute or relative quantification of 
specific targets. Absolute quantification is employed to reveal the original copy 
number of the target in the samples via a comparing the signal strength with a 
standard curve. On the other hand, in relative quantification; the amount of target 
template is compared to a control sample [29]. The relative quantification Real-Time 
PCR systems usually use relative fold change method for analyzing differences in 
gene expression. In this method a calibrator is selected among the samples and its 
expression is designated as 1X. The relative expression levels are obtained by first 
normalizing the expression levels via dividing the “Target gene” value with 
“Reference gene” value, and then dividing this normalized expression values of each 
8 
 
sample with the normalized calibrator value. The resulting values give the relative 
expression levels of the samples, such as an n fold change in expression according to 
the 1X sample. Both of the reference and target mRNA amounts are calculated from 
the standard curves prepared by 1/1, 1/10 and 1/100 dilutions of the calibrator 
sample. There are two points of great importance; firstly the calibrator sample should 
have the “normal” expression of the target gene. Secondly, it is very important to 
have sufficient amount of calibrator sample, which is used in every reaction [30]. 
1.6.1 Selection of the Endogenous Control 
The main principle of including an endogenous control in a Real-Time PCR reaction 
is to have an internal constant (an mRNA with invariable expression) simply to 
normalize the reactions for the amount of RNA used in the Reverse Transcription 
reaction. Many housekeeping genes account for good internal controls because their 
expression is hardly altered. Moreover, the internal control gene’s expression should 
also not be altered with any tested parameter in the experiment [31]. Relative gene 
expression evaluations can be applied safely, if the endogenous control is chosen as a 
gene with higher expression than the target gene. Some of the good internal controls 
for Real time PCR are; β-actin, β2-microglobulin and rRNA. GAPDH 
(Glyceraldehyde-3-Phosphate-Dehydrogenase) was also used frequently as internal 
controls but it is shown that the expression of GAPDH is increased in proliferating 
cells, so it is not reliable and should not be used especially in cancer research 
[31,32]. 
1.6.2 Properties of the Probes 
Probes used in this study were selected from Universal ProbeLibrary of Roche. 
These probes were hydrolysis probes that recognized sequences from human β2-
microglobulin and MEFV mRNA. The probes were pre-labeled by the supplier with 
a reporter dye FAM and a dark quencher dye. The probes were 8-9 bases long LNA 
(Locked Nucleic Acid) probes. LNA has a special chemistry, which allows very 
short oligonucleotides to be efficient in hybridization within real-time PCR studies. 
Because of the unusual chemistry of LNA, the annealing temperature of the probes 
are unexpectedly high for such short oligonucleotides. Another advantage of LNA 
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probes is that they are highly sequence specific, which makes them excellent for 
single-base mismatch recognition [33]. 
These probes are selected within exon spanning regions on the MEFV and β2-
microglobulin mRNAs. Since the probes are extremely short, the specificity of the 
reaction has to be achieved also with the primer sets used. The software available on 
the website of Universal ProbeLibrary (www.universalprobelibrary.com) helps 
researchers to select a set of specific primers in addition to a probe from the 
Universal ProbeLibrary that will provide the finest results [33]. 
1.7 Aim of the Study 
The aim of this study was to analyze the frequency of five most common mutations 
observed in MEFV (Mediterranean Fever) gene in a population of healthy elderly, to 
test if there is any statistical difference in their frequency occurrence from the normal 
population. A negative association was expected between healthy ageing and MEFV 
mutation frequencies. The genotyping results were compared with historical controls 
and also subgroup analyses for inflammation markers such as; RF (Rheumatoid 
Factor) and hsCRP (high sensitive C-Reactive Protein) value differences were done. 
Furthermore, in order to reveal any association between mutations and expression 
level of MEFV, a gene expression analysis was done with quantitative real-time 
PCR; the comparison was done between mutation carriers, wild type allele carriers 
and FMF patients with known MEFV mutations. Findings from this thesis are 
expected to reveal that, MEFV gene is not only a gene that causes FMF but rather a 
central gene in inflammatory response and the mutations in MEFV might disrupt the 
protein function or its expression level, causing imbalance in anti-inflammatory 
pathway and be the cause of many different chronic inflammatory diseases. 
  
 
10 
 
2. MATERIALS and METHODS 
2.1. Materials and Laboratory Equipment 
2.1.1. Used Equipments 
The laboratory equipment used during this project is listed in Appendix A. 
2.1.2. Used Chemicals, Enzymes, Markers and Buffers 
The chemicals, enzymes and markers used are given in Appendix B together with 
their suppliers. The compositions and preparation of buffers and solutions are given 
in Appendix C. 
2.1.3. Used Kits 
The kits used and their suppliers are given in Appendix D. 
2.2. Selection Criteria of the Healthy Elderly  
The study group is selected from the patients who come to general health check to 
the Geriatrics Polyclinic of Cerrahpaşa Medical Faculty. The patients were selected 
into the study group if they have satisfied the “healthy elderly criteria” based on the 
following aspects: 
1. The patient should be over 60. 
2. The patient should not have a history of any chronic inflammatory disease. 
3. The patient should be free of any acute or chronic inflammation at the time of 
the study. 
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4. The patient should not have any other disease than hypertension, 
osteoporosis, osteoarthritis. 
5. The patient’s functional capacity should be sufficient. 
2.3 Collection and Storage of Blood Samples 
The peripheral blood samples are collected from the patients, who came to the 
Geriatrics Polyclinic of Cerrahpaşa Medical Faculty, selected according to the 
healthy elderly criteria defined previously. The blood samples were collected in 
vacuum tubes containing EDTA. The samples were kept at −20 oC for short term 
storage (1-2 weeks), and in −80 oC for longer terms (several months) of storage. 
2.4 DNA Isolation from Human Whole Blood 
The DNA isolation was done by Magtration System 8Lx Instrument, with the kit 
provided by the supplier (Precision System Science). Approximately 4 mL of blood 
sample was used for each isolation. The isolated stock DNA was kept at -20 °C. 
2.5 DNA Amount, Purity and Working Solution Calculations 
The concentration and purity of the isolated DNA is calculated by using the 
absorbance values measured at 260, 280 and 320 nm. The concentration of the DNA 
is calculated with the equation 2.1 and the purity of the DNA samples are calculated 
with the equation 2.2 given below: 
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In order to have a set of DNA samples that have the same DNA concentration (50 
ng/µL), dilutions from the stock DNA are prepared (working solutions). The 
necessary amount of stock DNA solutions are calculated for 500 µL of 50 ng/µL 
working solutions (approximately 25 µg DNA).  
2.6. Polimerase Chain Reaction (PCR) 
PCR was used to amplify the target DNA sequences on MEFV gene which contained 
the related SNP regions. For this purpose the isolated genomic DNAs of the healthy 
elderly group were used as templates. A standard mixture of PCR (except from the 
primers) was used to amplify the related sequences of all five mutations. 
Table 2.1 Standard PCR mix 
Ingredient Stock Concentration Volume Final Concentration 
Taq Buffer  10X 2 µL  1X 
MgCl2  25 mM 1.5 µL  1.875 mM 
Forward Primer  10 pmol/µL 1 µL  0.5 µM  
Reverse Primer  10 pmol/µL 1 µL  0.5 µM  
dNTP mix  2 mM 0.4 µL  40 µM 
Taq Polymerase  5 U/µL 0.2 µL  0.05 U/µL 
dH2O  − 7.9 µL  − 
Template DNA  50 ng/µL 2 µL  100 ng 
Q Solution 5X 4 µL  1X 
FINAL  20 µL    
The performance of the PCR reaction is affected from the purity of the template 
DNA as well as the amplicon size (length) and content (GC%). 
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2.6.1 Template DNA 
Some of the isolated DNA samples contained heme and magnetic bead 
contamination. In order to purify such contaminated samples, the following 
procedure was followed: 
• 0.52 mL of protein precipitation solution (DNA Isolation Kit for Mammalian 
Blood, Roche) was added to each 1 mL of impure sample. 
• The mixture was vortexed for 25 seconds. 
• The mixture was centrifuged at 10.000 rpm for at least 10 minutes for 
precipitation of the proteins. 
• The supernatant was transferred to another tube, the volume of the 
supernatant was measured while transferring. 
• Absolute (100%) ETOH was added on the supernatant as 2X volume of the 
supernatant. 
• The new mixture was centrifuged at 2000 rpm for 10 minutes, the ETOH was 
cleaned with a micropipette. 
• The pellet was resuspended in 600 µL of 70% ETOH, without vortexing (for 
further cleaning of the DNA). 
• The mixture was centrifuged at 12.000 rpm for 5 minutes for DNA 
precipitation. 
• The ETOH was cleaned and the pellet was left for drying. 
• The dried pellet was resuspended in ~400 µL TE buffer. 
2.6.2 Oligonucleotide Primers 
The oligonucleotide primers used in this study were selected from previous studies 
[34,35] and are given in the table 2.2 below. They are confirmed on Amplify 3X 
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software [36] that they actually bind to the related sequence on MEFV gene. The 
efficiency of binding and the amplicon sizes are also determined with this software. 
It is also important to analyze the primer sets for dimer formation. The hairpin, 
heterodimer and self dimer analysis of the primer sets are done and confirmed with 
the SciTools on the IDT DNA website [37]. 
Table 2.2 Oligonucleotide primers 
SNP Primer Sequence Amplicon 
Size 
Reference 
MEFV F-5'-ATATTCCACACAAGAAAACGGC-3' 
E148Q R-5'-GCTTGCCCTGCGCG-3' 
244 bp 
[33] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
M680I R-5'-AGGGCTGAAGATAGGTTGAA-3' 
360 bp 
[34] 
MEFV F-5'-GCTACTGGGTGGTGAT*CAT-3' 
M694V R-5'-AGGGCTGAAGATAGGTTGAA-3' 
215 bp 
[34] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
M694I R-5'-CTGGACGCCTGGTACTCATTTTT*C-
3' 
195 bp 
[34] 
MEFV F-5'-TGTATCATTGTTCTGGGCTCT-3' 
V726A R-5'-AGGGCTGAAGATAGGTTGAA-3' 
360 bp 
[34] 
2.6.3 PCR Cycle Conditions 
The PCR cycle conditions were modified according to the desired amplicon. Except 
from the PCR conditions of E148Q mutation, all the other mutations’ PCR cycle 
conditions were similar (Table 2.3). The only differences in the conditions were in 
annealing temperatures, caused by the usage of different primer sets. 
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Table 2.3 General PCR cycle conditions 
Repeat 
Number  
  
Degree  Time  Phase  
1 
94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
Variable 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 
72 °C  10 minutes  Final Extension  
2.6.4 PCR Optimization 
The PCR reactions usually need to be optimized for higher efficiency, amplification 
of the correct target and determination of appropriate annealing temperature for 
different primer sets. In this thesis, Mg2+ titration, Touchdown PCR and Gradient 
PCR methods were applied to optimize the PCR conditions.  
2.6.5 Magnesium (Mg2+) Titration 
Mg2+ is the cofactor of Taq DNA polymerase, as well as many DNA polymerases. 
The amplification efficiency changes within a scale of low to high concentrations of 
Mg2+. Frequent observations about the effect of Mg2+ concentration on PCR include 
the decrease in amplicon amount with low concentrations, and unspecific 
amplification of non-target regions with high concentrations. In order to obtain the 
appropriate amount of Mg2+ for a PCR reaction, Mg2+ titration should be applied. 
This procedure is usually done by setting up PCR mixtures that only differ in Mg2+ 
concentration. A used procedure for determination of Mg2+ concentration of M694I 
PCR is given in table 2.4 below. 
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Table 2.4 Magnesium titration  
Ingredient 1.5 mM 1.875 mM 2.0 mM 2.5 mM 3.0 mM 
MgCl2 (25 mM) 1.2 µL 1.5 µL 1.8 µL 2.4 µL 3.0 µL 
ddH2O 
12.2 µL 11.9 µL 11.6 µL 11.3 µL 11.0 µL 
F. Primer 
1 µL 1 µL 1 µL 1 µL 1 µL 
R. Primer 
1 µL 1 µL 1 µL 1 µL 1 µL 
10X buffer 
2 µL 2 µL 2 µL 2 µL 2 µL 
Taq 
0.2 µL 0.2 µL 0.2 µL 0.2 µL 0.2 µL 
dNTP 
0.4 µL 0.4 µL 0.4 µL 0.4 µL 0.4 µL 
Template 
2 µL 2 µL 2 µL 2 µL 2 µL 
2.6.6 Gradient PCR 
When appropriate annealing temperature is not known for a primer set, gradient PCR 
might be used to determine the optimum annealing temperature for a PCR reaction. 
In gradient PCR, the thermo cycler is set in such a way that the wells in the thermo 
cycler block have a gradient of temperature from high to low for the annealing phase 
of the cycles. So, a set of identical PCRs can be run in the same block with different 
annealing temperatures, which saves time and prevents multiple usage of the thermo 
cycler for the same optimization. When the PCR products are viewed with agarose 
gel electrophoresis, the PCR mixture that has the nearest annealing temperature to 
the optimum temperature should give the best band intensity. In this thesis, the 
gradient PCR was used to optimize the annealing temperature of M694I PCR, a 
gradient from 65 to 55 was used and the best bands were observed in 59 °C, and this 
temperature is used as the annealing temperature of M694I PCR for the rest of the 
studies. 
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2.6.7 Optimization with Q Solution and Betaine 
A significant amount of PCRs did not work with standard magnesium titrations, 
annealing temperature adjustments or purification of the template DNA. Q solution 
from Qiagen was used as a PCR enhancer for such reactions in this thesis. It was 
frequently used in M694V PCRs and in almost all E148Q PCRs. Q solution is an 
additional solution used in PCR that comes with commercial DNA polymerases of 
Qiagen. Another PCR enhancer, Betaine, which is also frequently used in PCRs as 
GC melts, was used in the absence of Q solution. The optimized PCR mixtures with 
appropriate concentrations of Q solution and Betaine is given in the Table 2.5 below. 
Table 2.5 PCR conditions with Q Solution and Betaine 
Ingredient Stock Concentration Volume Final Concentration 
Taq Buffer 10X 2 µL 1X 
MgCl2 25 mM 1.5 µL 1.875 mM 
Forward Primer 10 pmol/µL 1 µL 0.5 µM 
Reverse Primer 10 pmol/µL 1 µL 0.5 µM 
dNTP mix 2 mM 0.4 µL 40 µM 
Taq Polymerase 5 U/µL 0.2 µL 0.05 U/µL 
dH2O − 7.9 µL − 
Template DNA 50 ng/µL 2 µL 100 ng 
 
 
* Q Solution 5X 4 µL 1X 
* Betaine 5 M 4 µL 1 M 
FINAL 20 µL  
2.7 PCR Conditions of MEFV-E148Q Mutation 
The PCR conditions for the E148Q PCR is shown in the table 2.6 below.  
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Table 2.6 PCR conditions for E148Q  
Repeat 
Number 
Degree  Time  Phase  
1 96 °C  5 minutes  Initial Denaturation  
96 °C  30 seconds  Denaturation  
64 °C  30 seconds  Annealing  5 
72 °C  30 seconds  Extension  
96 °C  30 seconds  Denaturation  
62 °C  30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 72 °C  10 minutes  Final Extension  
2.8 PCR Conditions of MEFV-M680I, V726A and M694V Mutations 
The PCR conditions for the M680I, V726A and M694V PCRs were the same and are 
shown in the table 2.7 below.  
Table 2.7 PCR conditions for M680I, V726A and M694V  
Repeat 
Number  
  
Degree  Time  Phase  
1 
94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
55 °C 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 
72 °C  10 minutes  Final Extension  
2.9 PCR Conditions of MEFV-M694I Mutation 
The PCR conditions for the M694I PCR is shown in the table 2.8 below.  
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Table 2.8 PCR conditions for M694I  
Repeat 
Number  
 
Degree  Time  Phase  
1 
94 °C  5 minutes  Initial Denaturation  
94 °C  30 seconds  Denaturation  
59 °C 30 seconds  Annealing  35 
72 °C  30 seconds  Extension  
1 
72 °C  10 minutes  Final Extension  
2.10 Agarose Gel Electrophoresis of PCR Products 
The right percentage of an agarose gel is important for observing the PCR bands. In 
this thesis, all of the PCR products’ amplicon sizes are in a range between 195 to 360 
bp, which can be seen on a 1%  agarose gel. In order to observe the PCR products of 
the E148Q, M680I, V726A, M694I and M694V mutations, 1% mini or midi gels are 
prepared. Mini gels are prepared with 0.5 g agarose and 0.5 µg/mL ethidium bromide 
added into 50 mL of 1X TBE buffer, which is diluted from 10X stock TBE. 
Similarly, %1 midi gels are prepared with 1.5 g agarose and 0.5 µg/mL ethidium 
bromide added into 150 mL of 1X TBE buffer. 6 µL of PCR product is mixed with 1 
µL 6X loading dye and loaded into the wells. Gene ruler 1 kb marker (Fermentas) is 
used as DNA ladder in order to calculate the lengths of the PCR products. The gels 
are run in 1X TBE buffer, at 120V with power supplier, for at least 30 minutes. The 
gels are observed under UV light with a transilluminator, and pictures are taken with 
UV PhotoMW software. 
2.11 Restriction Enzyme Digestion of PCR Products 
The restriction enzyme digestions of the PCR products were done according to the 
protocol provided by supplier of the enzymes. Restriction enzyme digestions were 
also performed and confirmed in electronic environment with EnzymeX software 
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[38]. The general protocol is given in table 2.9 and the restriction enzymes and 
expected fragment sizes are given in table 2.10 below. 
Table 2.9 Restriction Enzyme Digestion mixture  
Ingredient 1X amount 
10X reaction buffer 2 µL  
ddH2O 5 µL  
Restriction Enzyme (10 U/µL) 1 µL 
Amplicon 12 µL  
Final Volume 20 µL  
The restriction enzyme mixture containing PCR products were kept at 37 °C 
overnight for digestion. Digestion, and the RE are inactivated by application of the 
mixtures to 80 °C for 30 minutes. 
Table 2.10 Restriction Enzymes used for each mutation and expected fragment sizes.  
Amplicon SNP  Restriction 
Enzyme  (bp)  
Expected Fragments 
Wild Type: 3 fragments (92+83+69) E148Q AvaI 244 
Mutant: 2 fragments (161+83) 
Wild Type: 2 fragments (126+234) M680I HinfI 360 
Mutant: 1 fragment (360) 
Wild Type: 2 fragments (200+15) M694V PagI 215 
Mutant: 1 fragment (215) 
Wild Type: 1 fragment (195) M694I MboII 195 
Mutant: 2 fragments (182+13) 
Wild Type: 1 fragment (360) V726A AluI 360 
Mutant: 2 fragments (320+40) 
2.12 Agarose Gel Electrophoresis of Restriction Enzyme Digested PCR Products 
The right percentage of the agarose gel is important for observing the restriction 
enzyme digested bands correctly. In this thesis, the RE digested bands are observed 
in agarose gels of concentrations between 1% to 4%, according to the size of the 
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products and the minimum band size difference to be discriminated. E148Q 
restriction enzyme digested products were viewed in 4%, M680I and V726A 
restriction enzyme digested products were viewed in 2%, M694I and M694V 
restriction enzyme digested products were viewed in 3.5% mini or midi agarose gels. 
In all of the restriction analyses except from E148Q, 12 µL of RE digested PCR 
product is mixed with 2 µL of 6X loading dye and loaded into the wells. The gels are 
run in 1X TBE buffer, at 120V, for at least 30 minutes. The gel pictures are taken 
with UV PhotoMW software. 
2.13. Genotyping 
The genotyping is done by analyzing the agarose gel photos of the RE digested PCR 
products for the five most common mutations observed in MEFV gene (E148Q, 
M680I, M694V, M694I, V726A). This was done separately and blindly by myself 
and by my advisor Dr Eda Tahir Turanlı. Each gel included two positive controls, 
one heterozygote carrier and one homozygote mutant. Low range marker 
(Fermentas) was added to decide the band sizes along with positive controls. The 
expected band patterns were decided via EnzymeX software, and these patterns are 
shown in figures 2.1 (E148Q), 2.2 (M680I), 2.3 (M694V), 2.4 (M694I) and 2.5 
(V726A) below. 
 
Figure 2.1 E148Q expected restriction enzyme fragments sizes and genotyping 
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Figure 2.2 M680I expected restriction enzyme fragments sizes and genotyping 
 
Figure 2.3 M694V expected restriction enzyme fragments sizes and genotyping 
 
Figure 2.4 M694I expected restriction enzyme fragments sizes and genotyping 
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Figure 2.5 V726A expected restriction enzyme fragments sizes and genotyping 
2.14 Expression Analysis 
2.14.1 Collection and Storage of Blood Samples 
The peripheral blood samples for expression analysis are collected both from the 
selected patients who came to the Geriatrics Polyclinic, and selected FMF patients 
carrying various mutations of MEFV from Rheumatology Polyclinic of Cerrahpaşa 
Medical Faculty. The blood required for the RNA isolation was collected in 
PAXgeneTM Blood RNA tubes in order to stabilize the RNA. 2.5 mL of blood was 
added into each PAXgeneTM tube and kept at −20 °C until isolation (at maximum six 
months). 
2.14.2 RNA Isolation from Whole Human Blood 
Total RNA of the case group was required for gene expression analysis with real-
time PCR, for this purpose the total RNA was firstly tried to be isolated from the 
blood collected in vacuum EDTA tubes, which were kept at −80 °C. But the RNA 
isolation yield was too low for further investigation, and we concluded that the RNA 
was possibly degraded. In order to stabilize the RNA, and to prevent degradation; 
PAXgeneTM Blood RNA system was used. The total RNA was isolated from the 
samples, with High Pure RNA Isolation kit of Roche. Normally, the PAXgeneTM 
tubes were recommended to be used with Qiagen RNA isolation kit, so the protocol 
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of High Pure RNA Isolation kit from Roche was modified for usage with 
PAXgeneTM Blood RNA system. Modified protocol is as follows: 
• The PAXgene tubes containing 2.5 mL of peripheral blood were centrifuged 
at 3500 rpm for 10 minutes. 
• The supernatant was removed and the pellet was resuspended in 5 mL of 
RNAse free dH2O by vortexing. 
• The tubes were centrifuged at 3500 rpm for 10 minutes. 
• The supernatant was removed and the pellet was resuspended in 400 µL 
sterile PBS and transferred to a 2 mL microfuge tube. 
• 800 µL Lysis/Binding buffer was added to the microfuge tube and mixed by 
turning the tube up and down. 
• A High Pure filter tube was inserted into a collection tube and the mixture 
was added on the upper reservoir of the column. 
• The tubes were centrifuged at 10,000 rpm for 15 seconds. 
• The liquid collected in the collection tube was discarded. 
• 150 µL DNase solution per sample was mixed in a separate tube (135 µL 
DNase incubation buffer and 15 µL DnaseI) 
• 100 µL of DNase was added onto each tube, and the tubes were incubated at 
15 − 25 °C for 15 minutes. 
• 750 µL Wash Buffer I was added on the filter tubes and centrifuged at 10,000 
rpm for 15 seconds, and the fluid was discarded. 
•  750 µL Wash Buffer II was added on the filter tubes and centrifuged at 
10,000 rpm for 15 seconds, and the fluid was discarded. 
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• 300 µL Wash Buffer II was added on the filter tubes and centrifuged at 
maximum speed for 2 minutes, and the fluid was discarded with the 
collection tube. 
• The filter tube was inserted into a 1.5 mL microfuge tube. 
• Approximately 80 µL of elution buffer was added to the filter tube and 
centrifuged at 10,000 rpm for 1 minute. 
• The isolated RNAs were used as templates for cDNA synthesis reaction, used 
RNAs were stored in −80 °C for later usage. 
2.14.3 cDNA Synthesis 
cDNA was synthesized from isolated total RNA via two different kits (Transcriptor 
First Strand cDNA synthesis Kit from Roche, and RevertAidTM First Strand cDNA 
synthesis Kit from Fermentas) with oligodT primers. The protocol used for 
Transcriptor First Strand cDNA synthesis Kit from Roche is as follows: 
• 1 µL of 50 pmol/µL anchored oligo (dT)18 primer and 5 µL of PCR grade 
dH2O were added on 7 µL total RNA isolated previously.  
• The template-primer mixture was denatured by keeping at 65 °C for 10 
minutes, and then the mixture is immediately taken on ice. 
• Then 4 µL 5X Transcriptor Reverse Transcription reaction buffer, 0.5 µL 40 
U/µL Protector RNase inhibitor, 2 µL dNTP mix (10 mM each), and 0.5 µL 
10U/µL Transcriptor Reverse Transcriptase is added as in the given order. 
• The mixture in the tube was mixed carefully (vortex usage was avoided). 
• The samples were spinned down with a microcentrifuge. 
• The samples were placed in a thermal cycler and the following conditions 
were programmed: 
o 30 minutes at 55 °C  
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o 5 minutes at 85 °C (for the inactivation of Reverse Transcriptase) 
• The reaction was then stopped by taking the tubes on ice. 
• The synthesized cDNAs were stored at -20 °C for later usage. 
The protocol used for and RevertAidTM First Strand cDNA synthesis Kit from 
Fermentas is as follows: 
• The reaction mixture containing 8 µL of total RNA, 1 µL of 0.5 µg/µL oligo 
(dT)18 primer and 3 µL DEPC treated was prepared by mixing on ice. 
• The mixture was mixed gently and spinned down for 3-5 seconds with a 
microcentrifuge. 
• The mixture was incubated at 70 °C for 5 minutes and cooled on ice. 
• 4 µL of 5X reaction buffer, 1 µL of Ribolock, 2 µL of 10 mM dNTP mix 
were added onto the mixture, which was still on ice. 
• The mixture was incubated at 37 °C for 5 minutes. 
• 1 µL of RevertAid M-MuLV Reverse Transcriptase (200 U/µL) was added to 
each tube, completing the final volume to 20 µL. 
• The mixture was incubated at 42 °C for 60 minutes and then at 70 °C for 10 
minutes to end the reaction. 
• The newly synthesized cDNAs are immediately placed on ice and stored at -
20 °C for later usage. 
2.14.4. Real-Time PCR 
Real Time PCR was performed to obtain the relative change in mRNA amounts of 
target gene (MEFV) between defined groups such as, mutation carriers, wild type 
allele carriers and FMF patients. The Real-Time PCR reaction was set with 
LightCycler® TaqMan Master Kit from Roche and the Reaction was performed in 
Roche LightCycler® 2.0 instrument. Calibration standards were prepared from a 
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cDNA sample with relatively higher concentration, as undiluted, 1/10 dilution and 
1/100 dilutions. For each sample two reactions were set including negative controls, 
one for the target gene (MEFV) and one for the reference gene (internal 
control−β2M-Beta 2 Microglobulin). Each reaction is set with its specific primers 
and probes. The internal control reaction was set in order to normalize the errors 
result from differences in total RNA amount. The optimized reaction ingredients for 
MEFV are given in table 2.11 and the optimized reaction ingredients for β2M is 
given in table 2.12. The Real-Time PCR, cycle conditions are given in the table 2.13 
below.  
Table 2.11 MEFV Real-Time PCR mixture  
Ingredient 1X volume Final Concentration 
Water 9.85 µL − 
UPL Probe #8 (10 µM) 0.15 µL 75 nM 
Forward Primer (10 µM) 0.5 µL 250 nM 
Reverse Primer (10 µM) 0.5 µL 250 nM 
TaqMan Master (5X) 4 µL 1X 
cDNA template 5 µL − 
Table 2.12 β2M Real-Time PCR mixture  
Ingredient 1X volume Final Concentration 
Water 9.4 µL − 
UPL Probe #64 (10 µM) 0.2 µL 100 nM 
Forward Primer (10 µM) 0.7 µL 350 nM 
Reverse Primer (10 µM) 0.7 µL 350 nM 
TaqMan Master (5X) 4 µL 1X 
cDNA template 5 µL − 
 
28 
 
Table 2.13 Real-Time PCR Cycle conditions 
Repeat Number Temperature Time Phase 
1 95 10 minutes Pre Incubation 
95 10 seconds Denaturation 
60 30 seconds Annealing 45 
72 1 second Extension 
2.14.5. Relative Quantification of the Samples 
The relative quantification of the samples is done by 2-ΔΔCT method. [29]. In this 
thesis the relative expression levels of MEFV gene were obtained by first calculating 
the average CT values from different experiments for internal control (β2M) and 
MEFV of each control (free of mutations, N=16), then the average of these average 
values is used as the normalizing CT for the cases with the mutations. The average CT 
values from different experiments for internal control (β2M) and MEFV of each case 
(mutants) are also calculated. Then, the ΔCT values for MEFV and β2M are 
calculated via subtracting the average CT values of cases from the previously 
obtained average control CT values (CTControl - CTCase). These obtained ΔCT values are 
then placed as the power of 2 (2ΔCT) and the expression levels are then calculated via 
dividing the 2ΔCT of “Target gene” (MEFV) with the 2ΔCT of “Reference gene” value, 
The resulting values give the relative expression levels of each sample, normalized 
with the values obtained from the control samples.  
2.15. Statistical Analysis 
P value (the level of significance) accounts for the probability of any difference 
observed between two data sets is only by chance. As a result, the lower the p value, 
the more evidence for rejecting the null hypothesis. In this thesis, the obtained data 
was designated into levels of significance according to the p value  intervals: 
If P>0.05, there is no significant difference 
29 
 
If P<0.05, the difference is significant 
If P<0.01, the difference is highly significant 
If P<0.001, the difference is extremely significant 
In addition to this, chi square (χ2) test is used to test the significance of the 
distribution of mutations between the healthy elderly and the historical controls. 
These tests are done with SPSS software (version 15.0). Lastly, odds ratio 
calculations were done with the online tool from Simple Interactive Statistical 
Analysis (SISA) [39]. Odds ratio is generally used to compare the probability of a 
certain event in two groups. An odds ratio of 1 implies that the condition (or event) is 
equally possible in both of the case and the control groups [40]. 
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3. RESULTS 
3.1 DNA Isolation Results 
In this thesis, Magtration System 8Lx DNA isolation procedure was followed for all 
the samples. The average DNA concentration obtained from Magtration System 8Lx 
instrument and kit is 252.9 ng/µL and average A260/A280 value is 1.8 (N=164). 
3.2 Demographic Data of the Healthy Elderly Group 
The healthy elderly group in this study was made up of mostly women (75 %) and 
had an average age of 74±0.5 (range 61-92). The percentages of having hypertension, 
osteoporosis, osteoarthrosis; and hsCRP and RF negativity are shown in table 3.1 
below. 
Table 3.1 Demographic properties of the Healthy Elderly Group 
Healthy Elderly                  N=170   
Gender Percentage 
Female 75% 
Male 25% 
Hypertension 69% 
Osteoporosis 52% 
Osteoarthrosis 29% 
hsCRP (IU/mL) hsCRP < 3 IU/mL: 72 % mean=2.8±0.3  
(range 0.16-43.5) 
RF (mg/dL) RF < 15mg/dL: 92 %  
(range <9.8 – 154)  
BMI 
Mean= 27.34 ±0.3 (range 14.67-40.89) 
Mean Age 
Mean=74±0.5 (range 61-92) 
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3.3 Genotype Analysis 
The genotyping is done according to the comparison of agarose gel results with the 
expected restriction enzyme digestion patterns. Sample PCR and restriction enzyme 
results for each mutation analysis are given in Appendix E.  
3.3.1 Statistical Mutation Analysis 
The obtained mutation data was used to compare the distribution of mutations 
between the healthy elderly and historical controls. No significant difference was 
found between the mutation frequencies among healthy elderly group and any of the 
historical controls, instead the data confirmed the previous studies. χ2 analysis was 
not significant for all but one mutation in which  an excess of M694I alleles were 
found significantly higher in healthy elderly population than in the historical controls 
(χ2 =3.6, P=0.05). There was no difference between mutation frequencies between 
females or males in this population. The observed allele frequencies are given in 
table 3.2 below.  
Table 3.2 . Frequency of five common MEFV mutations in the elderly population  
SNP 
N=164  
Number of Alleles 
Carrier Frequency 
(mutant genotypes) 
Allele Frequency 
M694V  6 3.7 % 1.8 % 
M694I  6 3.7 % 1.8 % 
M680I   2 1.2 % 0.6 % 
V726A  7 4.3 % 2.1% 
E148Q  17 10 % 5 % 
TOTAL 38 23 % (1/4) 11.3 % 
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Table 3.3 Mutation analysis – comparison with historical controls 
SNP 
N=164 the healthy 
elderly group of 
genetic analysis   
(328 chromosomes)  
Turkish Controls 
(N=100) 
(200 chromosomes) 
[16] 
Turkish Controls  
(N=49)  
(98 chromosomes)  
[17] 
M694V  6 / 1.8 %  3 / 1.5 %  3 / 3.06 % 
M694I  6 / 1.8 % 0 0 
M680I   2 / 0.6 %  5 / 2.5 % 0 
V726A  7 / 2.1 %  2 / 1 %  2 / 2.04 % 
E148Q  17 / 5.0 % 12 / 6 %  2 / 2.04 % 
TOTAL 38 / 11.3 % 22 / 11 %  7 / 7.14 % 
3.3.2 Subgroup Analysis 
Subgroup analyses of hsCRP and RF positivity among common MEFV mutations 
were done and hsCRP values were analyzed for two levels of positivity. In the first 
group, hsCRP values higher than 5 IU/mL were accepted as hsCRP positive (hsCRP 
> 5 IU/mL), and in the second group hsCRP values higher than 3 IU/mL were 
accepted as hsCRP positive (hsCRP > 3 IU/mL). In both of these analyses, hsCRP 
positivity was not found to be significantly different between M694V mutation 
carriers and non-carriers (χ2=2.834, p=0.092, OR=4.12 for hsCRP > 5 IU/mL, and 
χ2=1.275, p=0.258, OR=2.09 for hsCRP > 3 IU/mL). On the other hand, RF 
positivity was found highly significant (χ2=7.358, p=0.007, OR=5.41) in E148Q 
allele carriers compared to the non-carriers. The data tables of hsCRP and RF 
statistical-significance subgroup analyses are given in the tables 3.4, 3.5 and 3.6 
below.  
33 
 
Table 3.4 hsCRP positivity for hsCRP > 5 IU/mL-subgroup analysis  
hsCRP value 
Alleles 
(Low hsCRP) 
hsCRP ≤ 5 IU/mL 
(High hsCRP) 
hsCRP > 5 IU/mL  
MM  132 16 
MV  4 2 
TOTAL 136 18 
M
EF
V
 M
69
4V
 
Pearson χ2=2.834, DF =1, p=0.092          OR=4.12, 95% CI 0.69-24.33 
Table 3.5 hsCRP positivity for hsCRP > 3 IU/mL-subgroup analysis  
hsCRP value 
Alleles 
(Low hsCRP) 
hsCRP ≤ 3 IU/mL 
(High hsCRP) 
hsCRP > 3 IU/mL  
MM  105 42 
MV  3 3 
TOTAL 108 45 
M
EF
V
 M
69
4V
 
Pearson χ2=1.275, DF =1, p=0.258          OR=2.09, 95% CI 0.48-12.88 
Table 3.6 RF value subgroup analysis 
RF value  
Alleles 
(Low RF) 
RF ≤ 15 mg/UL  
(High RF) 
RF > 15 mg/UL  
EE  130 8 
EQ  12 4 
TOTAL 142 12 
M
EF
V
 E
14
8Q
 
Pearson χ2=7.358, DF =1, p=0.007          OR=5.41, 95% CI 1.41-20.64 
3.4 Expression Analysis 
The error rates of the Real-Time PCR reactions are about 10% and the efficiencies of 
these reactions are approximately 2 (given in table 3.7). The standard curves for 
MEFV and β2M are given in the figures 3.1 and 3.2 below.  
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Table 3.7 Error rates and efficiencies of MEFV and β2M Real-Time PCRs. 
 MEFV β2M 
Error Rate 0.105 0.116 
Efficiency 2.061 1.983 
 
Figure 3.1 Standard curve for MEFV 
 
Figure 3.2 Standard curve for β2M. 
When the mRNA levels are normalized and calibrated according to the endogenous 
control and the standard dilutions, relative expression levels were obtained. In the 
overall data, the lowest mRNA levels were observed in M694V homozygous mutants 
(N=7, 0.0055 Relative Expression Units), and the highest MEFV mRNA levels were 
observed in E148Q heterozygous mutants (N=7, 1 patient with FMF, 6 healthy 
control, 0.032 Relative Expression Units). M694V heterozygous mutants had 0.027 
relative expression units of mRNA (N=2, 1 patient with FMF, 1 healthy elderly). On 
the other hand, in the healthy elderly group without mutations, the relative 
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expression of MEFV mRNA was higher than M694V homozygous mutants, but 
lower than E148Q and M694V heterozygous mutants (N=16, 0.017 relative 
expression units). The graph showing relative expression of MEFV mRNA among 
described groups is shown in figure 3.3 below. 
 
Figure 3.3 Comparison of average MEFV mRNA levels between the M694V and 
E148Q mutations of MEFV, and Healthy Elderly group without specific mutations. 
The relative expression of MEFV was also compared between FMF patients with 
mutations (N=9, 0.0045 relative expression units) and healthy elderly with no 
mutations (N=16, 0.0175 relative expression units), and approximately four-fold 
decrease in MEFV mRNA level is observed in FMF patients compared to healthy 
elderlies without mutations. (Figure 3.4). Moreover, E148Q heterozygousity seemed 
to increase the MEFV mRNA level more than two-fold within the healthy elderly 
group (Figure 3.5). 
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Figure 3.4 Comparison of MEFV mRNA levels between FMF patients with 
mutations and Healthy Elderly group without specific mutations. 
 
 
 
Figure 3.5 Comparison of MEFV mRNA levels within Healthy Elderly group, 
healthy elderlies without mutations and E148Q heterozygous mutants.  
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4. CONCLUSION & DISCUSSION 
A negative correlation between healthy ageing and MEFV mutation frequencies was 
expected. But the mutation analysis, which is done in 164 cases, showed similar 
distributions of five most common mutations of MEFV in the healthy elderly group 
compared to the historical controls. As a result, no significant difference was found 
between the mutation frequencies among healthy elderly group and any of the 
historical controls, instead the data confirmed the previous studies. On the contrary 
to the expected frequencies, the M694I mutation was observed in a higher frequency 
in our group compared to the historical controls. It is known that the M694I mutation 
is more prevalent in populations with Arabic origin, so this observation might be 
caused by population stratification due to the fact that the historical control groups 
were studied in Aegean area. 
In addition to this, subgroup analyses were done for hsCRP and RF values with 
M694V and E148Q mutations in order. In the subgroup analysis for hsCRP and 
M694V mutation, the hsCRP positivity was not significantly different between 
M694V carriers and non-carriers for hsCRP values higher than 3 and 5 IU/mL. On 
the other hand, RF positivity (RF > 15 mg/UL) was found highly significant in 
E148Q allele carriers compared to the non-carrier healthy elderlies. This result 
supports the findings of other studies, which imply higher occurrence of E148Q 
mutations among RF related diseases (such as Rheumatoid Arthritis). Furthermore, 
increase in RF positivity with age is a common observation. Our findings suggest 
that MEFV mutations may contribute to the causation of this observation.  
The results obtained from the preliminary data from gene expression analysis which 
is done with quantitative real-time PCR, indicated that MEFV mRNA levels differ 
with mutation occurrence. Also, MEFV mRNA levels are found to be lower in FMF 
patients with certain mutations, which confirms previous studies. It is also found that 
different mutations in MEFV gene altered the mRNA levels differently. To be more 
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specific, it is observed that E148Q heterozygous mutation carriers have an increased 
MEFV mRNA level (more than two fold) compared to non-carriers within the 
healthy elderly group, whereas M694V homozygous mutants have decreased MEFV 
mRNA levels. Interestingly, M694V heterozygous mutants have a higher MEFV 
mRNA level compared to non-carriers, but this may be due to the fact that there are 2 
cases, which are heterozygous for M694V, and the data fluctuates within a large 
range. In summary, MEFV mRNA expression level changes with the presence of 
mutations. However further analysis should be done covering broader sample pool 
including, healthy carriers and people with FMF but free of mutations.  
When these results are combined with the preliminary data obtained from gene 
expression analysis, one might suggest that M694V mutation decreases MEFV 
mRNA level and may result in an inflammatory phenotype. Another suggestion 
might be that this mutation could cause mRNA instability which in order results in a 
lower level of MEFV mRNA. Moreover, the inflammatory effect of M694V 
mutation might be due to aberrant protein interactions, since this mutation is shown 
to be localized at caspase-1 interaction site. On the other hand, E148Q mutation of 
MEFV increases the MEFV mRNA level dramatically and causes the higher 
prevalence of rheumatoid factor, which is a sign of chronic inflammation. The 
E148Q mutation might change MEFV expression regulation that results in such a 
dramatic increase in MEFV mRNA production. This mutation is localized in the 
second exon of MEFV, which has a CpG island; and the E to Q mutation actually 
causes the disruption of a CpG motif in the DNA level, which may cause a difference 
in local DNA methylation pattern. It is known that the CpG islands in the 
mammalian genomes are methylated except from the promoter regions. Since the 
CpG island is in the second exon of the gene it might be related with the expression 
regulation of MEFV. If E148Q mutation, somehow inactivates the methylation in 
this region, it might lead to such overexpression of MEFV mRNA. The 
overexpressed MEFV mRNA, may then result in an increase in the RF level causing 
inflammation. Alternatively, observed decrease in MEFV mRNA in M694V carriers 
who suffer from FMF or other acute inflammation, may result in a decrease in the 
activity of Pyrin because of the site of the mutation or by directly decreased MEFV 
mRNA, which in turn leads to inflammation. 
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Findings from previous studies, our studies and our gene expression studies showing 
a change in MEFV gene product in general inflammation, led us to hypothesize that 
MEFV gene may not be only specific to FMF but may generally be involved in the 
inflammatory pathway.  
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APPENDIX A 
LABORATORY EQUIPMENT 
Balances    Precisa 620C SCS 
     Precisa BJ 610C 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments  E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes    Gilson Pipetman 20 µL 200 µl, 1000 µl 
     Thermo Finnpipette 10 µL,  
pH meter     Mettler Toledo MP220 
Real time PCR   Roche Lightcycler 2.0 
Spectrophotometer   PerkinElmer Lambda25 UV/VIS Spectrometer 
Thermo cycler   Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator   Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top 
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APPENDIX B 
CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol    Riedel-de Haën 
EtBr     Amresco 
MgCl2     Fermentas 
Na2HPO4.7H2O   Riedel-de Haën  
NaH2PO4    Riedel-de Haën 
NaOH     Riedel-de Haën 
Primers    IDT DNA 
NaCl     Carlo Erba 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
     Qiagen 
     Roche 
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ENZYMES 
AluI     Roche 
AvaI     Fermantas 
HinfI     Roche 
MboII     Fermantas 
PagI     Fermantas 
Taq DNA Polymerase  Fermentas 
     Qiagen 
     Roche 
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MARKERS 
Gene RulerTM 1 kb DNA Ladder    Fermentas 
 
 
Gene RulerTM DNA Ladder Low Range  Fermentas 
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APPENDIX C 
BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
Add 1.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
Add 4.5 µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Mini Agarose Gel (3%)  
Agarose     1.5 g 
TBE buffer (1X)   50 mL 
Add 1.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
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Midi Agarose Gel (3%)  
Agarose     4.5 g 
TBE buffer (1X)   150 mL 
Add 4.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
Mini Agarose Gel (4%)  
Agarose     2 g 
TBE buffer (1X)   50 mL 
Add 1.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (4%)  
Agarose    6 g 
TBE buffer (1X)   150 mL 
Add 4.5µL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
10X Phosphate Buffered Saline (PBS) 
NaCl     90 g 
Na2HPO4.7H2O   26.8 g 
NaH2PO4    3.2 g 
Add up to 1 L by ddH2O, and adjust the pH to 7.2 after every 1/10 dilution. 
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APPENDIX D 
USED KITS 
DNA Isolation  8 Lx Magtration® Genomic DNA kit 
RNA Isolation  Roche – High Pure RNA isolation kit 
cDNA synthesis kit Fermantas − RevertAidTM First Strand cDNA synthesis 
kit 
Roche – Transcriptor First Strand cDNA synthesis kit 
Real-Time PCR  Roche – LightCycler® TaqMan Master Kit   
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APPENDIX E 
SAMPLE PCR AND RESTRICTION ENZYME RESULTS 
 
Figure E.1 E148Q PCR results 
 
Figure E.2 E148Q Restriction Enzyme Digestion Results 
 
Figure E.3 M680I PCR results 
53 
 
 
Figure E.4 M680I Restriction Enzyme Digestion Results 
 
Figure E.5 M694V PCR results 
 
 
 
 
Figure E.6 M694V Restriction Enzyme Digestion Results 
 
 
 
Figure E.7 M694I PCR results 
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Figure E.8 M694I Restriction Enzyme Digestion Results 
 
Figure E.9 V726A PCR results 
 
 
Figure E.10 V726A Restriction Enzyme Digestion Results 
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